查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093059

抗穆氏管荷爾蒙檢測市場－2026-2032年全球市場預測

Anti-Mullerian Hormone Test Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗苗勒氏管激素檢測市場將成長至 7.4442 億美元，複合年成長率為 11.83%。

主要市場統計數據
基準年 2025 3.4021億美元
預計年份：2026年 3.813億美元
預測年份 2032 7.4442億美元
複合年成長率 (%) 11.83%

抗穆氏管荷爾蒙(AMH) 檢測已成為一項重要的臨床血液檢查，有助於評估卵巢儲備、輔助不孕症評估、指南控制性卵巢刺激以及製定生殖內分泌治療策略。 AMH 由發育卵泡內的顆粒細胞產生，可在整個月經週期中進行檢測，並廣泛用於提供有關卵泡活動的實際資訊。除輔助生殖技術外，AMH 檢測還用於評估卵巢症候群、原發性卵巢功能障礙、卵巢早衰以及監測接受生殖毒性治療後的生育能力。 AMH 檢測需求的成長源於生育延遲、生育服務利用率的提高、生殖健康意識的增強以及透過醫院、生育診所、檢測實驗室和數位醫療平台獲得診斷服務的管道日益增多。然而，AMH 並非自然受孕、卵子品質或懷孕結局的唯一預測指標，因此需要謹慎的臨床解讀。因此，該領域正在向循證檢測方案、標準化檢測法、臨床醫生教育以及將 AMH 結果與個人化生殖醫學聯繫起來的綜合決策支持轉變。

抗穆氏管荷爾蒙檢測領域的變革性變化

隨著不孕症治療從一次性療法轉向預防性和個人化的生育計劃，抗穆氏管荷爾蒙）檢測領域正經歷著變革。由於患者對生育功能保存、卵子冷凍和早期生育功能評估的關注度不斷提高，AMH檢測在臨床上日益受到重視。生殖醫學專家正在將AMH結果與年齡、卵泡計數、病歷、卵巢刺激反應和內分泌指標相結合，以提高諮詢的準確性。檢查室工作流程也在不斷發展，引入了自動化免疫檢測平台，提高了分析靈敏度，並實施了更嚴格的品管，旨在減少檢測間的差異。同時，監管機構和專家指南強調了AMH檢測的合理使用，特別是因為AMH值可能受到調查方法、荷爾蒙避孕、卵巢病變、體重指數（BMI）、化療暴露和臨床情況的影響。遠端醫療和居家檢體採集雖然擴大了檢測的可近性，但也凸顯了由醫師主導結果解讀和透明的病患教育的重要性。這些變化共同作用，意味著AMH檢測不再被視為單一的、孤立的生育指標，而是逐漸成為更廣泛的生殖健康體系的一部分。

人工智慧對AMH檢測的累積影響

人工智慧 (AI) 正開始影響抗穆氏管荷爾蒙(AMH) 檢測體系，它能夠改善卵巢儲備數據的解讀、整合和臨床決策應用。在生育治療領域，AI 模型可以將 AMH 水平與年齡、超音波卵泡計數、先前促排卵反應、內分泌指標、體重、治療史和胚胎數據整合，從而支持個性化的卵巢刺激方案，並降低卵巢反應不足和卵巢刺激症候群的風險。在檢查室環境中，AI 透過輔助品管、異常檢測、工作流程最佳化和時間序列結果審查，提高了高通量診斷環境的一致性。在患者導向的生殖健康平台中，AI 驅動的分診和教育工具可以幫助患者了解 AMH 檢測的最佳時機，並引導他們轉診至合格的臨床醫生進行結果解讀。 AI 的整體影響並非取代臨床判斷，而是提高準確性、效率和個人化程度。負責任的實施需要檢驗的演算法、多樣化的資料集、偏差評估、透明的模型效能、網路安全措施，以及嚴格遵守醫療設備、資料保護和臨床管治要求。

關鍵區域視角下的全球AMH偵測應用狀況

在亞太地區，都市化加快、高齡產婦增多、不孕症認知度提高以及輔助生殖技術服務的擴展，推動了卵巢儲備評估需求的成長，進而抗穆氏管荷爾蒙（AMH）檢測的快速普及。在生育醫療基礎設施完善的國家，AMH檢測已納入生殖內分泌科的常規診療流程；而在新興醫療體系中，私人實驗室和專科診所正在擴大AMH檢測的覆蓋範圍。在北美，AMH檢測的應用已較為成熟，這得益於成熟的生育診所、較高的生殖健康意識以及生殖醫學中內分泌檢測的廣泛應用。此外，該地區也強調實證諮詢，以避免將AMH值過度解讀為自然受孕的直接預測指標。在拉丁美洲，隨著生育診所網路的擴張、某些目的地醫療旅遊的增加以及生殖診斷服務的改善，輔助生殖技術正取得進展，但費用和專家資源的不平衡仍然是重要的障礙。在歐洲，健全的臨床管治、系統化的輔助生殖技術監管以及廣泛的檢測能力是其優勢所在，抗苗勒氏管激素（AMH）檢測通常與超音波和內分泌評估聯合使用。在中東，由於婦女健康服務和生育中心的擴張以及政府主導的醫療現代化，人們對輔助生殖技術的興趣日益濃厚，尤其是在高所得醫療體系中。在非洲，AMH檢測的普及程度不均衡，目前主要集中在都市區私立醫療機構和專業的生育中心，但有限的診斷基礎設施、高昂的費用以及生殖內分泌服務的可及性限制了其更廣泛的應用。

影響AMH偵測使用情況的關鍵區域見解

在東協地區，由於私人生育服務、醫療旅遊以及女性健康意識的提高，抗穆氏管荷爾蒙）檢測在主要大都市地區日益普及；然而，高度發達的醫療體系與資源匱乏的市場之間，AMH檢測的可及性仍然存在顯著差異。在海灣合作理事會（GCC）國家，由於對輔助生殖技術和生育力保存諮詢的需求不斷成長，透過對生育中心、先進診斷技術和女性健康計畫的投資，AMH檢測的普及程度正在提高。歐盟（EU）以高度監管和臨床標準化的環境為特徵，經常將AMH檢測納入生殖醫學方案、檢查室系統和病患諮詢流程。金磚國家（BRICS）的發展模式各不相同。中國和印度擁有龐大的患者群體和不斷完善的生育基礎設施。巴西正在擴大其輔助生殖技術網路，而俄羅斯則保持成熟的生殖醫療能力。南非雖然在先進的生育治療方面展現出區域領先地位，但在醫療保健可近性方面仍面臨差距。在七國集團（G7）國家，診斷的可近性普遍較高，某些醫療保健系統正在積極討論報銷和保險問題，檢查室高度自動化，AMH檢測在生育診所中廣泛應用。北約成員國與北美和歐洲的先進醫療保健系統高度重合，AMH檢測的普及尤為顯著，因為診斷法規、臨床指南和生殖醫學能力都支持標準化AMH檢測及其結果解讀。

各國抗穆氏管荷爾蒙檢測的關鍵訊息

在美國，抗穆氏管荷爾蒙）檢測廣泛應用於生育診所、生殖內分泌科以及各種便捷的診斷途徑。由於AMH檢測並不能保證妊娠結局，其主要用途是預測卵巢反應，因此，適當的諮詢的重要性日益凸顯。在加拿大，在規範的檢查室標準和公眾對保護生殖功能的日益關注的支持下，AMH檢測在專業生育診所的臨床應用正在顯著推進。在墨西哥，AMH檢測正透過私人生育診所和跨境生殖醫學的需求而不斷擴展。同時，巴西仍是拉丁美洲輔助生殖技術和生殖診斷的重要中心。在歐洲，英國廣泛將AMH檢測應用於生育力評估和治療方案製定，而德國則強調規範的檢查室品質和實證生殖醫學。法國已將AMH檢測納入結構化的生育治療流程，俄羅斯則擁有完善的生育服務體系。輔助生殖技術在義大利和西班牙發展迅速，其中西班牙因其先進的生育治療服務而備受認可。在亞太地區，中國在完善生育治療服務基礎設施的同時，也大力推廣生殖健康檢查；印度則透過都市區生育診所和連鎖診斷機構，增加了抗苗勒氏管激素（AMH）檢測。日本正積極在其老齡化人口中推廣AMH檢測，澳洲則將其應用於其完善的生育和女性健康服務體系中。韓國則將先進的臨床實驗室醫學與不斷提高的結婚年齡、低生育率以及人們對生殖保存日益成長的興趣相結合。

為行業領導者提供的實用建議

產業領導者應優先考慮以臨床責任抗穆氏管荷爾蒙，使其與檢驗的應用情境相契合，例如評估卵巢儲備、制定生育治療方案、評估卵巢症候群以及治療後生殖監測。診斷服務提供者應加強檢測方法的標準化，公佈按年齡和檢測類型分類的清晰參考範圍，並投資於外部品質評估，以提高結果的可比性。生育診所應結合卵泡計數、年齡、病歷和先前治療反應來評估 AMH 水平，而不是孤立地呈現 AMH 檢測結果。數位醫療服務提供者在 AMH 教育中必須避免使用確定性的語言，並引導患者獲得適當的臨床解讀。實驗室和醫療保健系統應透過便捷的檢體收集方式擴大檢測範圍，同時維持儲存鏈、品管和資料隱私方面的標準。人工智慧開發人員應在不同人群中檢驗預測工具，並按年齡層、種族、合併症和治療環境記錄其表現。政策制定者和保險公司應支持實證生殖診斷、臨床醫生培訓和病患教育，打擊錯誤訊息的傳播，並改善不孕症評估的公平獲取途徑。

調查方法

本執行摘要採用系統性的二手研究途徑撰寫，重點在於檢驗的臨床、監管和科學資訊來源。此調查方法包括：回顧抗穆氏管荷爾蒙(AMH) 生理學、卵巢儲備功能檢測、輔助生殖技術、卵巢症候群和生育力保存的同儕審查文獻；回顧生殖醫學和內分泌專家的臨床指南；評估與免疫檢測測定的性能、分析變異性和品質保證相關的臨床實驗室和國家醫療保健政策、生殖健康和診斷性的公開資訊。研究結果經過定性整合，以確定推動技術應用、臨床應用、技術趨勢、區域趨勢和營運考慮的因素。本分析有意排除了市場規模、市場佔有率、收入估計和預測。所有結論均基於實證的臨床效用、醫療保健基礎設施、診斷實踐和技術應用，而非推測性的商業性預測。

結論

抗穆氏管荷爾蒙(AMH) 檢測，若在適當的臨床背景下進行解讀，在現代生殖健康中扮演著日益重要的角色，能夠提供有關卵巢儲備和預期促卵巢反應的重要資訊。其重要性涵蓋生育治療、生育力保存、內分泌評估和個人化生殖諮詢等領域。未來的發展將取決於檢測方法的標準化、負責任的患者教育、與超音波和臨床數據的整合，以及經過嚴格檢驗的人工智慧驅動的決策支援系統。區域部署將繼續反映生育基礎設施、檢查室能力、經濟負擔、法規和認知水平的差異。對於醫療保健專業人員、實驗室和數位健康相關人員而言，策略重點很明確：在確保解讀品質的同時，提高檢測的可及性。 AMH 檢測只有在作為綜合生殖評估的一部分，並輔以臨床專業知識、透明溝通和循證診療路徑時，才能發揮其最大價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗穆氏管荷爾蒙檢測市場：依產品分類

  • 即時檢測
  • 自檢套件

第8章：抗穆氏管荷爾蒙檢測市場：依成分分類

  • 裝置
    • 桌面設備
    • 可攜式分析儀
  • 試劑和試劑盒
    • 客製化檢測
    • 標準檢測

第9章：抗穆氏管荷爾蒙檢測市場：依應用領域分類

  • 卵巢儲備評估
  • 卵巢症候群的診斷
  • 預測早期卵巢衰竭

第10章：抗穆氏管荷爾蒙檢測市場：依最終用戶分類

  • 診斷檢查室
  • 不孕症治療診所
  • 醫院
  • 研究機構

第11章：抗穆氏管荷爾蒙檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章抗穆氏管荷爾蒙檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：抗穆氏管荷爾蒙檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbexa Limited
  • Abcam PLC
  • Ansh Labs LLC
  • Athenese-Dx
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Chengdu VACURE Biotechnology Co., Ltd.
  • CTK Biotech, Inc.
  • Cusabio Technology LLC
  • Eagle Biosciences, Inc.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Europe NV
  • Goldsite Diagnostics Inc.
  • Healthy Human Labs Limited
  • Kamiya Biomedical Company
  • LifeSpan BioSciences, Inc.
  • London Gynaecology Limited
  • Meridian Bioscience, Inc.
  • Monobind Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Vitrosens Biotechnology Co., Ltd.
Product Code: MRR-BC3400CDF7AF

The Anti-Mullerian Hormone Test Market is projected to grow by USD 744.42 million at a CAGR of 11.83% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 340.21 million
Estimated Year [2026] USD 381.30 million
Forecast Year [2032] USD 744.42 million
CAGR (%) 11.83%

The anti-Mullerian hormone test has become a clinically important blood-based diagnostic tool for assessing ovarian reserve, supporting infertility evaluation, guiding controlled ovarian stimulation, and informing care pathways in reproductive endocrinology. Anti-Mullerian hormone, produced by granulosa cells in developing ovarian follicles, is widely used because it can be measured across the menstrual cycle and provides actionable insight into follicular activity. Beyond assisted reproductive technology, AMH testing is used in the evaluation of polycystic ovary syndrome, primary ovarian insufficiency, premature ovarian aging, and post-treatment fertility monitoring in patients exposed to gonadotoxic therapies. Demand for AMH testing is being shaped by delayed childbearing, rising use of fertility services, broader awareness of reproductive health, and the expansion of diagnostic access through hospitals, fertility clinics, reference laboratories, and digital care platforms. However, clinical interpretation requires caution because AMH is not a stand-alone predictor of natural conception, egg quality, or pregnancy outcome. The sector is therefore moving toward evidence-based testing protocols, standardized assays, clinician education, and integrated decision support that can translate AMH results into personalized reproductive care.

Transformative Shifts in the Anti-Mullerian Hormone Testing Landscape

The anti-Mullerian hormone test landscape is undergoing transformative change as fertility care shifts from episodic treatment toward proactive, personalized reproductive planning. Growing patient interest in fertility preservation, egg freezing, and earlier fertility assessment is increasing the clinical visibility of AMH testing, while reproductive specialists are integrating AMH results with age, antral follicle count, medical history, ovarian stimulation response, and endocrine profiles to improve counseling accuracy. Laboratory workflows are also evolving through automated immunoassay platforms, improved analytical sensitivity, and tighter quality controls designed to reduce inter-assay variability. At the same time, regulatory and professional guidance is emphasizing appropriate use, particularly because AMH values can be affected by assay methodology, hormonal contraception, ovarian pathology, body mass index, chemotherapy exposure, and clinical context. The rise of telehealth and home sample collection is expanding access, but it also increases the need for physician-led interpretation and transparent patient education. Collectively, these shifts are positioning AMH testing as part of a broader reproductive health ecosystem rather than a single isolated fertility indicator.

Cumulative Impact of Artificial Intelligence on AMH Testing

Artificial intelligence is beginning to influence the anti-Mullerian hormone test ecosystem by improving how ovarian reserve data are interpreted, combined, and applied in clinical decision-making. In fertility care, AI-enabled models can integrate AMH values with age, ultrasound follicle counts, prior stimulation response, endocrine markers, body weight, treatment history, and embryology data to support individualized ovarian stimulation protocols and reduce the risk of under-response or ovarian hyperstimulation. In laboratory environments, AI can assist with quality monitoring, anomaly detection, workflow optimization, and longitudinal result review, strengthening consistency across high-throughput diagnostic settings. In patient-facing reproductive health platforms, AI-driven triage and education tools can help individuals understand when AMH testing may be appropriate, while also prompting referral to qualified clinicians for interpretation. The cumulative impact of AI is not the replacement of clinical judgment but the enhancement of precision, efficiency, and personalization. Responsible adoption requires validated algorithms, diverse datasets, bias assessment, transparent model performance, cybersecurity safeguards, and strict compliance with medical device, data protection, and clinical governance requirements.

Key Regional Insights Across Global AMH Testing Adoption

Asia-Pacific is witnessing rapid adoption of anti-Mullerian hormone testing as urbanization, delayed parenthood, rising infertility awareness, and expanding assisted reproductive services increase demand for ovarian reserve evaluation. Countries with advanced fertility infrastructure are integrating AMH testing into routine reproductive endocrinology workflows, while emerging healthcare systems are expanding access through private laboratories and specialty clinics. North America demonstrates mature utilization driven by established fertility clinics, high awareness of fertility preservation, and broad use of endocrine testing in reproductive medicine; the region also emphasizes evidence-based counseling to avoid overinterpretation of AMH as a direct predictor of spontaneous pregnancy. Latin America is advancing through growing fertility clinic networks, increasing medical tourism in selected destinations, and improving access to reproductive diagnostics, although affordability and uneven specialist availability remain relevant barriers. Europe benefits from strong clinical governance, structured assisted reproduction regulation, and widespread laboratory capability, with AMH testing commonly used alongside ultrasound and endocrine assessment. The Middle East is experiencing rising interest due to expanding women's health services, fertility centers, and government-backed healthcare modernization, particularly in high-income health systems. Africa shows more heterogeneous adoption, with AMH testing concentrated in urban private healthcare and specialist fertility centers, while broader access is constrained by diagnostic infrastructure, cost, and limited reproductive endocrinology coverage.

Key Group Insights Shaping AMH Test Utilization

Within ASEAN, anti-Mullerian hormone testing is gaining traction as private fertility services, medical travel, and women's health awareness expand across major urban centers, though access varies significantly between highly developed systems and lower-resource markets. The GCC is strengthening adoption through investment in fertility centers, advanced diagnostics, and women's health programs, supported by rising demand for assisted reproductive technology and fertility preservation counseling. The European Union reflects a highly regulated and clinically standardized environment where AMH testing is frequently incorporated into reproductive medicine protocols, laboratory accreditation systems, and patient counseling pathways. BRICS countries present a diverse growth profile: China and India have large patient populations and expanding fertility infrastructure, Brazil has a growing assisted reproduction network, Russia maintains established reproductive medicine capabilities, and South Africa provides regional leadership in advanced fertility care while facing access disparities. G7 countries generally demonstrate high diagnostic availability, stronger reimbursement or insurance discussions in selected systems, advanced laboratory automation, and widespread use of AMH testing in fertility clinics. NATO member countries, overlapping substantially with North American and European advanced health systems, show strong adoption where diagnostic regulation, clinical guidelines, and reproductive medicine capacity support standardized AMH testing and interpretation.

Key Country Insights in Anti-Mullerian Hormone Testing

The United States shows extensive use of anti-Mullerian hormone testing across fertility clinics, reproductive endocrinology practices, and direct-access diagnostic pathways, with increasing emphasis on appropriate counseling because AMH is most useful for ovarian response prediction rather than guaranteeing fertility outcomes. Canada demonstrates strong clinical adoption in specialist fertility care, supported by regulated laboratory standards and growing public discussion around fertility preservation. Mexico is expanding AMH testing through private fertility clinics and cross-border reproductive care demand, while Brazil remains a key Latin American hub for assisted reproduction and reproductive diagnostics. In Europe, the United Kingdom uses AMH testing widely in fertility assessment and treatment planning, Germany emphasizes regulated laboratory quality and evidence-based reproductive care, France integrates testing within structured fertility pathways, Russia maintains established fertility service capability, Italy and Spain show strong assisted reproduction activity, and Spain is particularly recognized for advanced fertility treatment access. In Asia-Pacific, China is expanding reproductive health diagnostics alongside growing fertility service capacity, India is seeing rising AMH testing through urban fertility clinics and diagnostic chains, Japan uses AMH testing in a mature but aging population context, Australia applies it within well-developed fertility and women's health services, and South Korea combines advanced laboratory medicine with increasing attention to delayed marriage, low fertility rates, and fertility preservation options.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically responsible growth by aligning anti-Mullerian hormone testing with validated use cases in ovarian reserve assessment, fertility treatment planning, polycystic ovary syndrome evaluation, and post-treatment reproductive monitoring. Diagnostic providers should strengthen assay standardization, publish clear reference intervals by age and assay type, and invest in external quality assessment to improve result comparability. Fertility clinics should integrate AMH with antral follicle count, age, medical history, and prior treatment response rather than presenting results in isolation. Digital health providers should ensure that AMH-related education avoids deterministic language and directs patients toward qualified clinical interpretation. Laboratories and healthcare systems should expand access through convenient sample collection while maintaining chain-of-custody, quality control, and data privacy standards. AI developers should validate predictive tools in diverse populations and document performance across age groups, ethnicities, comorbidities, and treatment settings. Policymakers and payers should support evidence-based reproductive diagnostics, clinician training, and patient education to reduce misinformation and improve equitable access to fertility assessment.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified clinical, regulatory, and scientific sources. The methodology includes review of peer-reviewed literature on anti-Mullerian hormone physiology, ovarian reserve testing, assisted reproductive technology, polycystic ovary syndrome, and fertility preservation; examination of clinical guidance from professional reproductive medicine and endocrinology bodies; evaluation of laboratory medicine standards related to immunoassay performance, analytical variability, and quality assurance; and assessment of publicly available healthcare policy, reproductive health, and diagnostic access information across regions and countries. Insights are synthesized qualitatively to identify adoption drivers, clinical applications, technology trends, regional patterns, and operational considerations. The analysis deliberately excludes market sizing, market share, revenue estimation, and forecasting. All conclusions are framed around evidence-backed clinical utility, healthcare infrastructure, diagnostic practice, and technology adoption rather than speculative commercial projections.

Conclusion

The anti-Mullerian hormone test is increasingly central to modern reproductive health because it provides useful information on ovarian reserve and expected response to ovarian stimulation when interpreted in the right clinical context. Its relevance is expanding across fertility treatment, fertility preservation, endocrine evaluation, and personalized reproductive counseling. The next phase of development will be defined by assay standardization, responsible patient education, integration with ultrasound and clinical data, and carefully validated AI-enabled decision support. Regional adoption will continue to reflect differences in fertility infrastructure, laboratory capacity, affordability, regulation, and awareness. For healthcare providers, laboratories, and digital health stakeholders, the strategic priority is clear: improve access while safeguarding interpretation quality. AMH testing delivers the greatest value when positioned as one component of comprehensive reproductive assessment, supported by clinical expertise, transparent communication, and evidence-based care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Mullerian Hormone Test Market, by Product

  • 7.1. Introduction
  • 7.2. POC Testing
  • 7.3. Self-check Kits

8. Anti-Mullerian Hormone Test Market, by Component

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Benchtop Devices
    • 8.2.2. Portable Analyzers
  • 8.3. Reagents & Kits
    • 8.3.1. Customized Assays
    • 8.3.2. Standard Assays

9. Anti-Mullerian Hormone Test Market, by Applications

  • 9.1. Introduction
  • 9.2. Ovarian Reserve Assessment
  • 9.3. Polycystic Ovary Syndrome Diagnosis
  • 9.4. Premature Ovarian Failure Prediction

10. Anti-Mullerian Hormone Test Market, by End User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Fertility Clinics
  • 10.4. Hospitals
  • 10.5. Research Institutes

11. Anti-Mullerian Hormone Test Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Anti-Mullerian Hormone Test Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Anti-Mullerian Hormone Test Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbexa Limited
  • 15.2. Abcam PLC
  • 15.3. Ansh Labs LLC
  • 15.4. Athenese-Dx
  • 15.5. Bio-Rad Laboratories, Inc.
  • 15.6. Bio-Techne Corporation
  • 15.7. bioMerieux S.A.
  • 15.8. Chengdu VACURE Biotechnology Co., Ltd.
  • 15.9. CTK Biotech, Inc.
  • 15.10. Cusabio Technology LLC
  • 15.11. Eagle Biosciences, Inc.
  • 15.12. Elabscience Bionovation Inc.
  • 15.13. Epitope Diagnostics, Inc.
  • 15.14. F. Hoffmann-La Roche Ltd.
  • 15.15. Fujirebio Europe N.V.
  • 15.16. Goldsite Diagnostics Inc.
  • 15.17. Healthy Human Labs Limited
  • 15.18. Kamiya Biomedical Company
  • 15.19. LifeSpan BioSciences, Inc.
  • 15.20. London Gynaecology Limited
  • 15.21. Meridian Bioscience, Inc.
  • 15.22. Monobind Inc.
  • 15.23. Siemens Healthineers AG
  • 15.24. Thermo Fisher Scientific Inc.
  • 15.25. Tosoh Corporation
  • 15.26. Vitrosens Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SELF-CHECK KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SELF-CHECK KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SELF-CHECK KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BENCHTOP DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENCHTOP DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BENCHTOP DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PORTABLE ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PORTABLE ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PORTABLE ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CUSTOMIZED ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CUSTOMIZED ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CUSTOMIZED ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STANDARD ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STANDARD ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STANDARD ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OVARIAN RESERVE ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OVARIAN RESERVE ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OVARIAN RESERVE ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYCYSTIC OVARY SYNDROME DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYCYSTIC OVARY SYNDROME DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYCYSTIC OVARY SYNDROME DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREMATURE OVARIAN FAILURE PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMATURE OVARIAN FAILURE PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREMATURE OVARIAN FAILURE PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FERTILITY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FERTILITY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FERTILITY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 105. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 106. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 107. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 126. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 127. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 155. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 163. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 245. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025